Error loading player: No playable sources found
64237
Plenary Session 5: Challenges with Incoming Materials - Raw, Starting, Ancillary, etc.
Date
June 28, 2023
This product is not available for individual purchase, but it is available as part of the following products:
The Cell and Gene Therapy Products (CGTP) Symposium: Manufacturing, Quality and Regulatory Considerations enables the exchange of scientific ideas and dialogue with regulators that form the basis of evolving regulatory practices in the development of these diverse and innovative products…
Raw material selection decisions early in the development of ATMPs are crucial and can impact the final product quality and ultimately patient safety. Therefore, it is imperative that developers employ a risk-based approach when selecting and qualifying materials to establish the necessary controls to ensure process robustness and safety of the product.
Material classification is key to a successful implementation of a risk-based approach. The same material (e.g. plasmids) may be classified differently according to its use in different products and thus warrant a different control strategy. Classification of materials should be considered early in development with input from regulators as appropriate. Current guidance from many regulatory and standards bodies including FDA, EU, ICH, PIC/S, USP, and Ph. Eur., provide a foundation though some inconsistencies and use of alternate terminology do exist.
Control strategies for materials should be commensurate to their classification and, therefore, their potential to affect critical quality attributes of the product. Suppliers are an extension of an ATMP developer’s manufacturing process and the rigor of suppliers’ qualification activities and controls can impact the manufacturing process and the product. As suppliers are often unfamiliar with therapeutic manufacturing requirements (e.g. the need to minimize or eliminate the use of animal-derived materials),a partnership mindset by both parties to ensure transparency and joint mitigation of risks is crucial.
Session Speakers:
Material Considerations for The Manufacture of Pluripotent Stem Cell Derived Products
Saran Karumbayaram, CBER, FDA
Challenges and Perspectives in the Manufacture of Synthetic sgRNA used in Cell and Gene Therapy
Joe Guiles, Agilent Technologies Inc.
Material Qualification from a CDMO Perspective: A Phase Appropriate Approach to Material and Component Risk Control
Athenesia Faggins, WuXi Advanced Therapies
Material classification is key to a successful implementation of a risk-based approach. The same material (e.g. plasmids) may be classified differently according to its use in different products and thus warrant a different control strategy. Classification of materials should be considered early in development with input from regulators as appropriate. Current guidance from many regulatory and standards bodies including FDA, EU, ICH, PIC/S, USP, and Ph. Eur., provide a foundation though some inconsistencies and use of alternate terminology do exist.
Control strategies for materials should be commensurate to their classification and, therefore, their potential to affect critical quality attributes of the product. Suppliers are an extension of an ATMP developer’s manufacturing process and the rigor of suppliers’ qualification activities and controls can impact the manufacturing process and the product. As suppliers are often unfamiliar with therapeutic manufacturing requirements (e.g. the need to minimize or eliminate the use of animal-derived materials),a partnership mindset by both parties to ensure transparency and joint mitigation of risks is crucial.
Session Speakers:
Material Considerations for The Manufacture of Pluripotent Stem Cell Derived Products
Saran Karumbayaram, CBER, FDA
Challenges and Perspectives in the Manufacture of Synthetic sgRNA used in Cell and Gene Therapy
Joe Guiles, Agilent Technologies Inc.
Material Qualification from a CDMO Perspective: A Phase Appropriate Approach to Material and Component Risk Control
Athenesia Faggins, WuXi Advanced Therapies
Session Chairs
General
Tracks
Related Products
Keynote Presentation
Gene Therapy Drug Development for Ultra-Rare Disease: Challenges & Opportunities
Parallel Session 10: Platform Development Approaches for AAV Gene Therapy Products
With the recent approval of several Adeno-Associated Virus (AAV)-based gene therapies, the application of AAV gene therapy approaches to the treatment of human disease is expanding…
Plenary Session 12: Updates in the Regulatory Landscape for Cell & Gene Therapy Products
Several cell and gene therapy products have received marketing approval from health authorities and, with that, a more complete picture is now emerging about the regulatory CMC requirements to commercialize these products…
